Epidemiology of Prescriptions for Neuroleptic Drugs: Tranquilizers rather than Antipsychotics

Lindén, Michael; Thiels, Cornelia

doi:10.1055/s-2001-15880

Cited by 36 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The availability of second-generation antipsychotic agents with improved anxiolytic properties over first-generation agents (24), while oftering less sedation (25), has likely contributed to their clinical role in the treatment of anxiety disorders (11). The availability of antipsychotics with fewer shortterm anticholinergic and extrapyramidal effects than firstgeneration antipsychotics (26) may have also contributed to the observed increases.…”

Section: Discussionmentioning

confidence: 97%

“…Potential adverse effects of antipsychotics, including metabolic, endocrine, and cerebrovascular risks, have been well documented (7)(8)(9), Sedative properties associated with antipsychotic medications (10) may help to explain their broadened use in nonpsychotic patients. Some have suggested that from a pharmaco-epidemiological perspective, these drugs should be considered "antineurotic" or "hypnotic" medications rather than antipsychotics (11), In this context, patients presenting with anxiety disorders represent a large potential population for antipsychotic treatment. Clinical guidelines recommend serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as first-line pharmacologie treatments for anxiety disorders (12), although a significant number of patients do not respond to an adequate trial of these medications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

Comer¹,

Mojtabai²,

Olfson³

2011

AJP

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

Comer¹,

Mojtabai²,

Olfson³

2011

AJP

View full text Add to dashboard Cite

show abstract

“…Polysomnographic sleep studies in such patients have consistently documented changes in a variety of sleep parameters, including reduced total sleep time (TST), sleep efficiency, increased sleep fragmentation, sleep latency, and, more variably, reduced slow wave sleep and rapid eye movement (REM) sleep (Caldwell and Domino 1967;Zarcone et al 1987;Bench et al 1992;Lauer et al 1997;Keshavan et al 1998). So far, few studies have investigated the influence of antipsychotics on polysomnographically recorded sleep, despite altered sleep in schizophrenia and the widespread off-label use of such drugs for the treatment of sleep disturbance (Linden and Thiels 2001). Conventional antipsychotics, such as chlorpromazine, pimozide and haloperidol, generally improve measures of sleep continuity in schizophrenia (Kaplan et al 1974;Gillin et al 1977;Keshavan et al 1996;Maixner et al 1998) but frequently demonstrate extrapyramidal side effects.…”

Section: Introductionmentioning

confidence: 98%

Sleep-promoting properties of quetiapine in healthy subjects

et al. 2004

View full text Add to dashboard Cite

The aim of this study was to investigate the effects of quetiapine, an atypical antipsychotic, on polysomnographic sleep structure and subjective sleep quality. This double-blind, placebo-controlled, randomized cross-over study investigated the polysomnographic sleep structure and subjective sleep quality of 14 healthy male subjects given placebo, quetiapine 25 mg or quetiapine 100 mg. Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Treatment was administered orally 1 h before bedtime on nights 1 and 2. Quetiapine 25 mg and 100 mg significantly improved sleep induction and continuity under standard and acoustic stress conditions. Increases in total sleep time, sleep efficiency, percentage sleep stage 2 and subjective sleep quality were seen. A significant increase in periodic leg movements during sleep was observed with quetiapine 100 mg. The sleep-improving properties of quetiapine may be important in counteracting different aspects of psychopathology in schizophrenia and other disorders. These sleep-inducing and sleep-modifying properties are probably related to quetiapine's receptor-binding profile, including its antihistaminergic, antidopaminergic and antiadrenergic properties. Other mechanisms might be relevant as well and further investigation is required.

show abstract

“…20,21 Somnolence is a side effect of quetiapine treatment, leading to prescription in an off-label fashion when this side effect is desired. 22 The somnolence effect of quetiapine is thought to arise from its 5-HT 2 and H 1 receptor blockade capabilities, similar to those of medications used as sedatives, including the antidepressants mirtazapine, trazodone, and trimipramine. Qualitative sleep studies using the Pittsburgh Sleep Quality Index (PSQI) have shown improvements in the sleep quality of depressed patients after initiation of quetiapine therapy.…”

mentioning

confidence: 99%

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression

Gedge

Lazowski²,

Murray³

et al. 2010

NDT

View full text Add to dashboard Cite

Objective:To determine the effect of adjunctive quetiapine therapy on the sleep architecture of patients with bipolar or unipolar depression. Methods: This is a prospective, single-blind, repeated measures polysomnographic study. Sleep architecture was analyzed by overnight polysomnography, and subjective sleep quality was measured using the Pittsburgh Sleep Quality Index. The Hamilton Rating Scale for Depression, Montgomery Asberg Depression Rating Scale, Young Mania Rating Scale, and Clinical Global Impression-Severity Scale were employed to quantify changes in illness severity with adjunctive quetiapine treatment. Polysomnographs and clinical measures were administered at baseline, after 2-4 days of treatment, and after 21-28 days of quetiapine treatment. The average dose of quetiapine was 155 mg, ranging from 100-200 mg. Results: Adjunctive quetiapine therapy did not significantly alter sleep efficiency, sleep continuity, or Pittsburgh Sleep Quality Index scores. Respiratory Disturbance Index and percentage of total time in rapid eye movement (REM) sleep significantly decreased and the percentage of total time in non-REM sleep, and duration of Stage 2 and non-REM sleep significantly increased after 2-4 days of quetiapine treatment. Illness severity significantly decreased over time. Conclusions: Adjunctive quetiapine treatment alters sleep architecture in patients with major depressive disorder or bipolar disorder, which may partially explain its early antidepressant properties. Changes in sleep architecture are more robust and significant within two to four days of starting treatment.

show abstract

Epidemiology of Prescriptions for Neuroleptic Drugs: Tranquilizers rather than Antipsychotics

Abstract: Evaluation is urgently needed for those uses of neuroleptic drugs that, from a pharmacoepidemiological perspective, must be seen as their primary indication.

Cited by 36 publications

References 2 publications

National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

Sleep-promoting properties of quetiapine in healthy subjects

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression

Contact Info

Product

Resources

About